Cohance Lifesciences investing $18 million in NJ Bio, Aruka Bio to sharpen focus on ADC
The investments will aid in deeper integration of NJ Bio’s customer-facing services and focused development of Aruka’s proprietary pipeline through potential partnerships. Both the transactions will be funded through internal accruals.
· 9/4/2026, 9:33:13 AM· 2 min read
The investments will aid in deeper integration of NJ Bio’s customer-facing services and focused development of Aruka’s proprietary pipeline through potential partnerships. Both the transactions will be funded through internal accruals.
Read original story →Related stories
business
Stock up on food to prepare for extreme weather, minister warns
business
The Ayurveda Co shuts down: founders confirm ₹250 crore venture’s closure after rapid expansion
business
Cipla inks partnership with China’s Qilu Pharma for cancer biosimilar
business